JHOC 4 Urology

Johns Hopkins University is a renowned academic institution based in Baltimore, MD, offering a wide range of undergraduate and graduate programs across various disciplines. With a focus on research and innovation, the university is dedicated to providing students with a rigorous and comprehensive education to prepare them for future success in their chosen fields. Generated from their business information

Laryngologist Simon Best specializes in voice and airway disorders, including the comprehensive care of professional voice-users and performers. He treats patients diagnosed with recurrent respiratory papillomatosis (RRP), vocal cord paralysis, laryngeal cancer, precancerous vocal cord dysplasia, benign laryngeal lesions (polyps, cysts, nodules), and laryngeal and tracheal stenosis. He has expertise in the operative management of vocal cord disorders, including Blue Light laser surgery and office-based management of vocal cord papilloma, dysplasia and vocal cord paralysis. Dr. Best earned a medical degree from the Yale School of Medicine and completed residency training in Otolaryngology–Head and Neck Surgery at the Johns Hopkins University School of Medicine. He undertook fellowship training in laryngology at Massachusetts General Hospital. Dr. Best has a particular clinical and research interest in recurrent respiratory papillomatosis and sees patients from across the country for specialized care for this disorder. He offers operative and office-based laser for papilloma, utilizing the Blue Light laser, which allows for precise excision of papilloma while preserving underlying vocal function. Dr. Best is also a pioneer in the adjuvant use of bevacizumab for RRP, helping many patients break the cycle of repeated surgeries. The Best Laboratory studies RRP and the development of novel immunotherapies to target the underlying viral infection. This research is conducted in collaboration with the head and neck cancer and cervical cancer research groups at Johns Hopkins, which also study human papillomavirus-related diseases. In addition, Johns Hopkins is a site for ongoing clinical trials in DNA immunotherapy, the goal of which is to eliminate the causative viral infection that leads to RRP.

Dr. Streiff's major clinical interest involves the prevention and treatment of venous thromboembolism. He has written several comprehensive reviews on vena caval filters and the management of venous thromboembolism in cancer patients. He chairs the Venous Thromboembolism Guideline Committee for the National Comprehensive Cancer Center Network and has served on international consensus panels to develop standardized guidelines for the use of vena caval filters in the management of venous thromboembolism. As a member of a Johns Hopkins Evidence-Based Practice Center panel, he participated in the development of evidence reports on the management of venous thromboembolism. His research on patients with malignant gliomas identified ABO blood group as a novel risk factor for VTE in this population. A multicenter clinical trial is now nearing completion to confirm these results and identify plasma markers of increased risk for venous thromboembolism in glioma patients. As Medical Director of the Anticoagulation Management Service and Outpatient Clinics, he and his colleagues from the Department of Pharmacy have been actively involved in developing policies and procedures for standardizing anticoagulation management and guidelines for VTE prevention at the Johns Hopkins Medical Institutions. As the consulting Hematologist for the Johns Hopkins Comprehensive Hemophilia Treatment Center, he is actively involved in the diagnosis and treatment of patients with hemophilia, von Willebrand disease and other hemostatic disorders.